Form 8-K - Current report:
SEC Accession No. 0000950170-25-040232
Filing Date
2025-03-17
Accepted
2025-03-17 16:05:10
Documents
13
Period of Report
2025-03-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K gyre-20250317.htm   iXBRL 8-K 50508
2 EX-99.1 gyre-ex99_1.htm EX-99.1 454294
3 GRAPHIC img51893664_0.jpg GRAPHIC 41470
  Complete submission text file 0000950170-25-040232.txt   700006

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT gyre-20250317.xsd EX-101.SCH 25992
15 EXTRACTED XBRL INSTANCE DOCUMENT gyre-20250317_htm.xml XML 4684
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 25744374
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)